Mar. 16 at 5:28 AM
$SENS An interesting overview of the companies shaping the blood glucose monitoring landscape.
However, one cannot help but observe that innovation in diabetes care is not solely about technological capability — it is equally about leadership, strategic execution, and commercial competence.
Some of the companies listed here have demonstrated extraordinary ability to scale, commercialise, and continuously iterate their technologies. Others, unfortunately, possess remarkable technology but appear constrained by management teams that have struggled to translate innovation into meaningful market penetration and shareholder value.
For the sake of patients, healthcare systems, and investors alike, one hopes that companies with outstanding technology but underperforming governance will eventually see the strategic changes required to unlock their full potential.
The opportunity within the global CGM market is far too important to be squandered.
